🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Novo Nordisk reports 24% sales jump, driven by diabetes and obesity treatments

Published 06/11/2024, 06:52 pm
© Reuters.
NOVOb
-
NVO
-

Investing.com -- Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in Danish kroner and 24% at constant exchange rates, reaching DKK 204.7 billion. 

“The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,” said president and CEO of Novo Nordisk, Lars Fruergaard Jørgensen, in a statement.

The company’s diabetes and obesity care segment saw a 25% jump in sales, totaling DKK 191.8 billion. 

Within this, obesity care alone rose by an impressive 44%, largely due to Wegovy's success, which witnessed a 76% surge to DKK 38.3 billion. 

Similarly, diabetes care, supported by GLP-1 products like Ozempic and Rybelsus, also contributed to this increase, particularly in North America, where sales in this segment grew by 31%.

Novo Nordisk's operating profit showed a comparable upward trend, climbing by 21% in Danish kroner and 22% at CER, reaching DKK 91.6 billion. 

Despite challenges like periodic supply constraints across various markets, the company maintained a strong operating margin of 44.7%, reflecting its successful commercial execution strategies and positive pricing effects. 

In North America, sales were positively influenced by gross-to-net adjustments from previous years, while in international markets, obesity care product uptake further bolstered growth​.

Novo Nordisk also advanced its R&D initiatives, particularly with the SOUL cardiovascular outcomes trial, which confirmed the efficacy of oral semaglutide in reducing major adverse cardiovascular events for diabetes patients. 

In obesity research, the company completed a phase 2a trial for monlunabant and anticipates phase 2b trials in 2025, aiming to expand treatment options for a global patient base.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.